Alkermes has reported positive detailed results from the phase 2 Vibrance-2 study of alixorexton in adults with narcolepsy type 2, showing significant improvements in wakefulness and excessive daytime sleepiness compared with placebo. The findings, presented at SLEEP 2026 in Baltimore, mark the first large phase 2 study of an orexin 2 receptor agonist to demonstrate…
13-second eye test may help predict recovery of consciousness after severe brain injury
A 13-second bedside eye test could help clinicians predict whether patients with severe brain injuries are likely to regain consciousness, according to research presented at the European Academy of Neurology Congress 2026 in Geneva. The findings suggest that a little-studied part of the pupil’s reaction to light, known as the late light-off response, may offer…
Hearing aids linked to lower dementia risk in people with epilepsy
Adults with both epilepsy and hearing loss who use hearing aids may have a 23% lower risk of developing dementia than those who do not, according to research presented at the European Academy of Neurology (EAN) Congress 2026. Hearing loss is recognised as the largest modifiable risk factor for dementia, but evidence that hearing aids…
New study reveals different drivers behind rising numbers of Parkinson’s, multiple sclerosis and motor neuron disease
The growing number of people living with Parkinson’s disease (PD), multiple sclerosis (MS) and motor neuron disease (MND) is being driven by different underlying factors, according to new research due to be presented at the European Academy of Neurology (EAN) Congress 2026 and published in Neurology [1,2]. Researchers from France and Sweden analysed nationwide health…
Sarah Tabrizi recognised in King’s Birthday Honours for Huntington’s disease research
Professor Sarah Tabrizi has been appointed a Commander of the Order of the British Empire (CBE) in the 2026 King’s Birthday Honours in recognition of her services to people with Huntington’s disease and her pioneering contributions to neurological research. Professor Tabrizi is a Group Leader at the UK Dementia Research Institute (UK DRI) at UCL,…
Choose Neurology
People are often frightened of neurological conditions, and that goes for clinicians as well as patients! Neurophobia is well documented among medical students and non-neurologist doctors. Neurology is often perceived as complex and intimidating. Project Neurology was launched with the goal of tackling Neurophobia among (primarily) students, trainees and early career doctors. However, what started…
Teva files FDA application for ecopipam in paediatric Tourette syndrome
Teva Pharmaceutical Industries has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for ecopipam, an investigational treatment for paediatric Tourette syndrome. The company says the submission marks a significant milestone for what could become the first new FDA-approved therapy for children and adolescents with Tourette syndrome in more than…
MS relapses remain rare after age 60 whether DMTs are continued or stopped
A long-term study suggests that people with multiple sclerosis (MS) aged over 60 may face a very low risk of relapses regardless of whether they continue taking disease-modifying therapies (DMTs) or discontinue treatment. Researchers found that clinical disease activity remained uncommon in both groups, although MRI scans frequently revealed changes that warrant further investigation. The…
Peppermint oil shows potential to lower blood pressure in new study
Researchers at the University of Lancashire have reported that peppermint oil may offer a simple and inexpensive way to reduce mildly elevated blood pressure, following the results of a new clinical study published in PLOS One. The study found that participants who consumed 100 microlitres of peppermint oil twice daily for 20 days experienced an…
Tourettes Action launches #NoChoice campaign to challenge misconceptions about Tourette syndrome
Tourettes Action has launched its national #NoChoice campaign for Tourette’s Awareness Month 2026, aiming to improve public understanding of Tourette syndrome and reduce the stigma experienced by people living with the condition. Running from 15 May to 15 June, the campaign highlights a central message: Tourette’s is not a choice, but how society responds is….
